Under the agreement, the companies will share the U.S. responsibility to develop and commercialize Synta's lead compound STA-4783, a first-in-class, small-molecule, oxidative stress inducer, for metastatic melanoma, the most deadly form of skin cancer. (BioWorld Today)

Under the agreement, the companies will share the U.S. responsibility to develop and commercialize Synta's lead compound STA-4783, a first-in-class, small-molecule, oxidative stress inducer, for metastatic melanoma, the most deadly form of skin cancer. (BioWorld Today)

NPS Pharmaceuticals Inc. and AstraZeneca plc mutually agreed to end their six-year partnership to discover and develop drugs targeting metabotropic glutamate receptors (mGluRs). (BioWorld Today)

NPS Pharmaceuticals Inc. and AstraZeneca plc mutually agreed to end their six-year partnership to discover and develop drugs targeting metabotropic glutamate receptors (mGluRs). (BioWorld Today)